GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials

BACKGROUND: The main objective of phase I cancer clinical trials is to identify the maximum tolerated dose, usually defined as the highest dose associated with an acceptable level of severe toxicity during the first cycle of treatment. Several dose-escalation designs based on mathematical modeling o...

Descripción completa

Detalles Bibliográficos
Autores principales: Dinart, D., Fraisse, J., Tosi, D., Mauguen, A., Touraine, C., Gourgou, S., Le Deley, M. C., Bellera, C., Mollevi, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Software
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469913/
https://www.ncbi.nlm.nih.gov/pubmed/32580715
http://dx.doi.org/10.1186/s12911-020-01149-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469913/
https://www.ncbi.nlm.nih.gov/pubmed/32580715
http://dx.doi.org/10.1186/s12911-020-01149-3

Ejemplares similares